Pharmaceutical Water Systems — Working Principle, Tests, Limits & Validation
A practical guide for production, QA and utilities engineers explaining design, operation, testing and compliance of Purified Water (PW), Highly Purified Water (HPW) and Water for Injection (WFI).
1. Water grades used in pharma (short)
Purified Water (PW)
Used for non-parenteral formulation, equipment washing and buffer preparation. Typically produced by RO + polishing (EDI/DI + UV + filtration).
Water for Injection (WFI)
Required for parenteral/sterile manufacture (drug product or process requiring endotoxin control). Historically produced by distillation; EP now allows validated membrane routes that meet WFI risks. 1
Highly Purified Water (HPW)
An EP term for membrane-produced water with WFI-like quality used where WFI is not strictly required but very high purity is needed.
2. Overall system architecture — unit operations & purpose
Typical pharmaceutical water systems purify municipal/potable feed water in stages, produce bulk PW/WFI, store it in a sanitary tank and distribute via a recirculating loop to points-of-use (POU). Main stages:
- Pretreatment — suspended solids removal, activated carbon (chlorine removal), softener or antiscalant if feed hardness is high, and coarse filtration (5–10 µm).
- Primary purification — reverse osmosis (single or double/double-pass RO) to remove dissolved ions, microbes and organics.
- Polishing — EDI or mixed-bed ion exchange to lower conductivity; UV (254 nm) to reduce TOC; submicron filtration or ultrafiltration as microbiological barrier.
- WFI production — by distillation (multi-effect or vapor-compression) OR by validated membrane-based sequences in jurisdictions/contexts where EP/WHO accept non-distillation WFI (requires robust biofilm & endotoxin control). 2
- Storage & distribution — sanitary storage tank (vent filters), heated recirculating loop (hot loop 65–80 °C) or cold loop with strict sanitization, continuous recirculation to prevent stagnation.
Process flow (simplified)
Feed (Potable)
→
Pretreatment (C, Softener, 5–10µm)
→
RO (1st) → RO (2nd/DP)
→
EDI / UV / UF (Polish)
→
Storage Tank → Distribution Loop → POUs
Note: WFI may be produced by a distillation step after pretreatment or by a validated membrane route. The route must address endotoxin and biofilm control. 3
3. Key analytical tests & why they matter
Regulatory compendia and guidance emphasise a combination of chemical, organic and microbiological tests to demonstrate water quality and to detect trend changes early.
3.1 Total Organic Carbon (TOC) — USP <643>
Purpose: detect and limit organic contaminants that may come from feedwater, polymeric leachables, disinfectant by-products, biological metabolites, or organic process residues.
- Compendial context: USP guidance designates a target system suitability response equivalent to a 500 µg C/L (500 ppb C) standard. Instrument qualification, system suitability testing and method suitability are required — TOC analyzers must meet detection/precision criteria. 4
- How measured: Catalytic oxidation or UV-persulfate oxidation with nondispersive infrared or chemiluminescence carbon detection. Prepare and verify SST standards (500 ppb) per USP method.
- Interpretation: TOC is a limit/indicator — trending and investigations for spikes are critical.
3.2 Conductivity — USP <645>
Purpose: measure ionic impurities; conduct complementary Stage tests in the compendial method.
- USP three-stage test: Stage 1 (non-temp-compensated online monitoring), Stage 2 (temperature-equilibrated measurement at ~25 °C; Stage-2 pass criterion commonly referenced as ≤ 2.1 µS/cm), Stage 3 (if needed, pH/KCl adjustment test). The method and stages must be followed for compendial compliance. 5
- Online monitoring: continuous conductivity is standard for trend and alarm; final compliance is determined by compendial sampling and testing approaches where required.
3.3 Endotoxin (Bacterial Endotoxins Test, USP <85>)
Purpose: detect Gram-negative bacterial lipopolysaccharide (endotoxin) which can cause pyrogenic reactions in parenteral products.
- WFI used for parenterals must be controlled for endotoxin. Typical action/alert levels and routine testing frequencies are set by site risk assessment and product needs. Standard LAL or recombinant alternatives are used. (See compendial chapter and internal SOPs.)
3.4 Microbiological testing
Purpose: detect and trend viable contamination (heterotrophic bacteria, yeasts and molds) and to support endotoxin/sterility risk assessments.
- Methods: membrane filtration with low-nutrient media, pour/plate methods or rapid methods where validated.
- Action levels: compendia do not set a single pass/fail numeric limit for PW/WFI; sites set scientifically justified alert/action limits derived from qualification/PQ data and regulatory expectations. Guidance documents and regulators often indicate very low counts for WFI (for example, FDA references an agency action level of <10 acceptable="" action="" an="" as="" cfu="" contexts="" in="" level="" li="" many="" ml="">
4. Typical acceptance limits — quick reference
| Attribute | Purified Water (bulk) | WFI (bulk) |
|---|---|---|
| TOC | Target system suitability response equivalent to ≤ 500 µg C/L (500 ppb) standard (per USP guidance) | Same TOC target approach; WFI has additional endotoxin control requirements. 7 |
| Conductivity | Stage-2 compendial testing: commonly ≤ 2.1 µS/cm at 25 °C (follow USP <645> test procedure) | Same Stage-2 conductivity acceptance approach where applicable. 8 |
| Endotoxin | Not typically required for PW (set by risk assessment) | Controlled and monitored; typical control guidance for parenteral use — specific limits set by site/product risk (compendial methods for LAL/rFC). |
| Microbiological | Site-specific alert/action limits (example practice: ≤ ~100 CFU/mL alert for PW in some operations) | Very low levels expected; industry/regulators commonly use action levels such as <10 a="" action="" as="" cfu="" in="" justify="" level="" ml="" monitoring="" practical="" td="" vmp.=""> |
5. Sampling plan & monitoring strategy (practical)
- Sample points: feed, post-pretreatment, post-RO, post-EDI (if present), storage tank, loop return, selected POUs (sterile and non-sterile points). Map points in P&ID and extract POUs for trending.
- Frequencies: continuous for conductivity/temperature; TOC daily or per site SOP; microbiology & endotoxin daily-to-weekly at representative POUs (frequency based on product risk and historical performance).
- Technique: aseptic sampling technique, sterile containers, rapid transport to lab, validated sample handling to avoid false positives. Use low-nutrient media for environmental relevance.
- Trending: use control charts (Shewhart or EWMA) with site-specific alert/action limits; investigate excursions and apply corrective actions with root cause analysis.
- Sanitization: hot sanitization (if loop heated) or periodic chemical/oxidative/ozone sanitization for cold loops; UV and UF are supplemental barriers but do not replace good hygienic design and sanitization. 10
6. Qualification & validation essentials
System qualification follows DQ → IQ → OQ → PQ. Key elements to cover in protocols and reports:
- Design Qualification (DQ): process description, P&ID, materials of construction (no dead legs, sanitary welds, sloped returns), sizing and heat tracing design for hot loops.
- Installation Qualification (IQ): vendor docs, piping/material verification, instrumentation calibration, and HART/P&ID verification.
- Operational Qualification (OQ): verify unit ops (RO rejection, EDI performance, distillation steam quality if present), alarms, interlocks, control strategies, and SST for TOC/conductivity instruments.
- Performance Qualification (PQ): demonstrate system can meet acceptance limits under normal production conditions and seasonal feedwater variation; collect microbial, TOC, conductivity and endotoxin data; develop routine monitoring plan and alert/action limits.
- SST & instruments: TOC analyzers must be qualified with appropriate SST solutions (500 ppb standard for TOC). Conductivity meters must be verified per USP procedures for stage testing. 11
7. Common problems & practical fixes
- Rising conductivity: check CO₂ ingress (improperly equilibrated samples), exhausted polishing resin/EDI issues, RO membrane damage or casing leaks; verify the compendial two/three stage conductivity test procedure is followed for compliance measurement. 12
- TOC spikes: upstream carbon breakthrough, new polymer components after maintenance, failed UV lamp, or contaminated sample containers — re-sample and check SST and analyzer performance. 13
- Microbial excursions: dead-legs, low velocity or stagnation, inadequate sanitization schedule — increase recirculation velocity, remove dead-legs, and sanitize loop; review hygienic design and right-size tank/loop velocities per WHO/industry guidance. 14
- Endotoxin presence in WFI: suspect biofilm in membrane systems or a breach in aseptic components; for membrane WFI, demonstrate endotoxin control through validated UF/UF barriers, sanitization and trending. 15
8. Example SOP checklist for daily operators (short)
- Check and log feed pressure, RO permeate flow, recirculation loop flow and temperature.
- Verify conductivity and TOC instrument states, run SST checks weekly as per lab SOP.
- Visual tank checks (no leaks, vents intact, no debris in sight glasses), verify spray-ball operation if in-use.
- Record sanitization events (hot/chemical/ozone) and any corrective actions.
- Escalate any trending alarms per the defined alert/action matrix in VMP.
9. Regulatory & guidance highlights (must-read)
- WHO — Annex 3, TRS 1033: Good Manufacturing Practices: Water for Pharmaceutical Use. Comprehensive lifecycle guidance for design, commissioning, monitoring and control of water systems. 16
- USP — Water FAQs & Chapters: Guidance on TOC (USP <643>) and conductivity (USP <645>) procedures and system suitability requirements. Read and apply instrument SST procedures carefully. 17
- European Pharmacopoeia (EP) revision: EP allows validated non-distillation (membrane) routes for producing WFI where appropriate—requires robust justification and control of biofilm/endotoxin risk. 18
